aff
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results2023· article· en· Nature Medicine· Medicine
564
citations
Every work in the frame. Each row carries the routes that admitted it, because a frame that forgets how it found something cannot be audited.